Research any topic before you write.

Find related topics. | Discover entities. | See connections. | Build a topical map.

Vicriviroc

Vicriviroc, previously named SCH 417690 and SCH-D, is a pyrimidine CCR5 entry inhibitor of HIV-1. It was developed by the pharmaceutical company Schering-Plough. Merck decided to not pursue regulatory approval for use in treatment-experienced patients because the drug did not meet primary efficacy endpoints in late stage trials. Clinical trials continue…

Companies, HIV-1 background & Clinical trials

Use the mouse wheel or two fingers (on touchscreens) to zoom in and out of the map.

Research this topic

Explore the main themes, entities and connections around Vicriviroc. Start with the topic map, then use the sections below for research and deeper semantic analysis.

Explore this topic

Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.

HIV-1 background

11 related topics

Clinical trials

3 related topics

SCH-C and vicriviroc

2 related topics

Concerns surrounding CCR5 antagonists

1 related topics

Topics to explore

Browse the full topic structure. Each item opens a new analysis centered on that subject.

Overview

HIV-1 background

SCH-C and vicriviroc

Clinical trials

Concerns surrounding CCR5 antagonists

Advanced semantic analysis

Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.

Map overview Semantic statistics

Vicriviroc

Nodes30
Edges29
Triples55
Avg. degree1.93
Density0.066667
Components1

How this topic connects Entity context

See the strongest relationship patterns around the current topic before diving into the raw triples.

Vicriviroc

Top relations

related to Method of action · 15
Vicriviroc → Additionally, Binding, CCR5, E238, I198, It, Other, Specific, Specifically, TM3, TM5, TM6, TM7, Y108, Y251
related to SCH-C and vicriviroc · 11
Vicriviroc → CCR5, HIV-1, However, In, QT, QTc, SAR, SCH, SCH-C, Schering-Plough, When
related to Concerns surrounding CCR5 antagonists · 10
Vicriviroc → Available, CCR5, CXCR4, HIV, HIV-1, However, In, Studies, Two, V3
related to Clinical trials · 8
Vicriviroc → Currently, HIV RNA, HIV-1, HIV-infected, II, Phase II, R5-infected, The
related to background · 5
Vicriviroc → CCR5, HIV, HIV-1, However, The
instance of · 1
Vicriviroc → CCR5 inhibitors

Important terminology Word statistics

Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.

Important terminology

ccr5 hiv-1 gp120 coreceptor virus patients hiv trials viral cell two may however antagonists gp41 cxcr4 target one entry clinical

Entity relationships Subject–Predicate–Object triples

SubjectPredicateObjectConfidenceSrc
vicrivirocinstance ofCCR5 inhibitors0.80text
as well as other entry inhibitors of HIV-1instance ofCCR5 inhibitors0.80text
inhibit the initial stages of the virus life cycle.HIV-1 entryHIV binds toinstance ofCCR5 inhibitors0.80text
fuses with the target T-cells or macrophages with the help of gp120instance ofCCR5 inhibitors0.80text
gp41instance ofCCR5 inhibitors0.80text
the only two proteins that are currently known to be exhibited on the surface of the viral envelopeinstance ofCCR5 inhibitors0.80text
Vicrivirocrelated to backgroundThe0.60section
Vicrivirocrelated to backgroundHIV0.60section
Vicrivirocrelated to backgroundHowever0.60section
Vicrivirocrelated to backgroundCCR50.60section
Vicrivirocrelated to backgroundHIV-10.60section
Vicrivirocrelated to Clinical trialsCurrently0.60section

Related concept clusters Concept neighborhoods

These clusters group vocabulary that occurs around closely connected concepts in the source material.

    Connections between topic areas Semantic bridges

    Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.

    Min side: 3
    For writers, content strategists, SEOs, marketers and creators — from quick topic research to advanced semantic analysis.